南方医科大学学报Issue(12)：1842-1845,4.DOI:10.3969/j.issn.1673-4254.2014.12.29
肾移植受者应用霉酚酸酯的合理治疗窗
Therapeutic window of mycophenolate mofetil for preventing acute graft rejection following renal transplantation
摘要
Abstract
Objective To determine the optimal dose range (therapeutic window) of mycophenolate mofetil (MMF) for preventing acute graft rejection following renal transplantation. Methods The trough concentration of MMF (MPA-C0) at 12 h after oral administration of the drug (two doses daily given at an interval of 12 h) was monitored in 110 renal transplant recipients within a month, in 2-3 months, and over 4 months after the transplantation using EMIT method. The occurrence of acute graft rejection and drug toxicity were observed in all the patients during the one-year follow-up. Results The incidence of acute graft rejection after transplantation was 13.64%(15/110) in these patients. Drug toxicity and complications occurred in 32.73%(36/110) of the patients, including 12 cases with reduced white blood cell counts, 10 with MMF cid-associated diarrhea, 10 with infection, 4 with liver function damage. Acute rejection was successfully reversed after methylprednisolone treatment and drug toxicity was managed by corresponding treatment and adjustment of MMF dose. No deaths or graft removal occurred in these patients. The ROC curve showed that a MPA-C0 of 1.40-2.80 mg/L was optimal in preventing acute rejection after the transplantation and reducing adverse drug effects. Conclusion Monitoring MPA-C0 and individualized MMF dosing help to prevent acute graft rejection, reducing drug toxicity and complications, and improving graft survival rate after renal transplantation.关键词
肾移植/霉酚酸酯/谷浓度/治疗窗Key words
renal transplantation/mycophenolate mofetil/trough concentration/moderate dose引用本文复制引用
于立新,周敏捷,罗敏..肾移植受者应用霉酚酸酯的合理治疗窗[J].南方医科大学学报,2014,(12):1842-1845,4.基金项目
国家自然科学基金（81350009，81450032）；广东省科技计划项目（2012B031800470） Supported by National Natural Science Foundation of China (81350009,81450032) （81350009,81450032）
